Cantor Fitzgerald started coverage on shares of Zosano Pharma (NASDAQ:ZSAN) in a research note released on Monday, Benzinga reports. The firm issued an overweight rating and a $3.66 target price on the biotechnology company’s stock. Cantor Fitzgerald also issued estimates for Zosano Pharma’s FY2019 earnings at ($3.74) EPS and FY2020 earnings at ($2.74) EPS.
Several other analysts also recently issued reports on ZSAN. ValuEngine downgraded Zosano Pharma from a buy rating to a hold rating in a report on Tuesday, January 29th. Maxim Group initiated coverage on Zosano Pharma in a report on Wednesday, April 17th. They set a buy rating and a $8.00 price objective on the stock.
Shares of Zosano Pharma stock opened at $3.89 on Monday. Zosano Pharma has a 52 week low of $1.85 and a 52 week high of $6.65.
Zosano Pharma (NASDAQ:ZSAN) last issued its quarterly earnings results on Thursday, March 14th. The biotechnology company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.16).
In related news, CEO John Peter Walker acquired 100,000 shares of the business’s stock in a transaction on Thursday, April 11th. The shares were purchased at an average price of $3.50 per share, for a total transaction of $350,000.00. Following the acquisition, the chief executive officer now owns 280,228 shares in the company, valued at $980,798. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.71% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of ZSAN. Exencial Wealth Advisors LLC purchased a new position in Zosano Pharma during the 4th quarter valued at about $34,000. Dimensional Fund Advisors LP purchased a new position in Zosano Pharma during the 3rd quarter valued at about $121,000. Telemetry Investments L.L.C. grew its stake in Zosano Pharma by 37.8% during the 4th quarter. Telemetry Investments L.L.C. now owns 219,040 shares of the biotechnology company’s stock valued at $464,000 after acquiring an additional 60,069 shares in the last quarter. Finally, Aisling Capital Management LP purchased a new position in Zosano Pharma during the 4th quarter valued at about $3,392,000. Hedge funds and other institutional investors own 41.93% of the company’s stock.
About Zosano Pharma
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology. Its lead product candidate is M207, a proprietary formulation of zolmitriptan used for the treatment of migraine.
Recommended Story: What is the QQQ ETF?